ArticleJournal of cachexia, sarcopenia and muscle2023
The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer.
Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017-2018.Abdominal radiology (New York) · 2026Article
- Predictive Value of the Inflammatory Burden Index for Pathological Complete Response in HER2-Positive and Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy: A Comparative Analysis with Conventional Inflammatory Indices.Journal of clinical medicine · 2026Article
- ALNCR.TNM as a Novel Prognostic Tool for Cancer Survival.Journal of cachexia, sarcopenia and muscle · 2026Article
- Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Systemic inflammation and liver fibrosis as predictors of surgical outcomes in colorectal cancer liver metastasis: a biomarker-based survival study.Updates in surgery · 2026Article
- Article
- Preoperative pan-immune-inflammation value and geriatric nutritional risk index predict outcomes of elderly patients with endometrial carcinoma after radical surgery.BMC women's health · 2026Article
- Innovative Inflammatory Burden Index for identification of high mortality risk in patients with pulmonary embolism: a large retrospective cohort study.BMJ open respiratory research · 2026Article
- Systemic inflammatory indices and 28-day mortality in severe pneumonia: a retrospective single-center exploratory study.Frontiers in medicine · 2026Article
- A prognostic nomogram integrating preoperative IBI and MAR with clinicopathological factors for gastric cancer patients after radical gastrectomy.Frontiers in surgery · 2026Article
- Comparison of PNI and GNRI nomogram models for predicting postoperative complications in elderly patients with lung cancer: a retrospective study.Frontiers in nutrition · 2026Article
- Association of fat-free mass index and survival in patients with lung cancer: a multicenter cohort study.International journal of clinical oncology · 2026Article
- Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.Frontiers in endocrinology · 2026Article
- Development and Validation of a Pathomics-Based Prognostic Model for Patients with Lung Adenocarcinoma Undergoing First-Line EGFR-TKI Therapy.Annals of surgical oncology · 2026Article
- Systemic Immune-Inflammation Index is Associated with Pressure Injury in Hospitalized Patients with Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Cancer management and research · 2026Article
- Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study.Frontiers in cardiovascular medicine · 2026Article
- Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer.Frontiers in endocrinology · 2026Article
- Association Between Dietary Magnesium Intake and Low Muscle Mass: The Mediating Role of Inflammatory Indicators.Healthcare (Basel, Switzerland) · 2025Article
- Assessment of frailty and inflammatory burden index as predictors of postoperative IAA in elderly appendectomy patients.BMC surgery · 2025Article
- Associations of inflammatory burden index with the prevalence and mortality of asthma in adults: a population based study.Journal of thoracic disease · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSystemic inflammation, the most representative tumour-host interaction, plays a crucial role in disease progression and prognosis in patients with non-small cell lung cancer (NSCLC). Few studies have compared the performance of existing haematological systemic inflammation biomarkers in predicting the prognosis of NSCLC patients. The purpose of this study was to compare the prognostic value of existing systemic inflammation biomarkers and determine the optimal systemic inflammation biomarker in patients with NSCLC through a multicentre prospective study.
methodsThe predictive accuracy of systemic inflammation biomarkers for prognostic assessment in NSCLC was assessed using C-statistics. Inter-group differences in survival were assessed using the log-rank test and visualized using the Kaplan-Meier method. A restricted cubic spline (RCS) curve was used to explore the association between the biomarkers and survival. Independent prognostic biomarkers for overall survival were determined using multivariable Cox proportional hazards regression analysis. Logistic regression analysis was used to determine independent predictors of 90-day outcomes, length of hospitalization, hospitalization expenses and cachexia.
resultsThe inflammatory burden index (IBI) had the highest C-statistic for predicting the prognosis of patients with NSCLC, reaching 0.640 (0.617, 0.663). Patients with a high IBI had significantly worse outcomes than those with a low IBI (35.46% vs. 57.22%; log-rank P < 0.001). The IBI was also able to differentiate the prognosis of patients with NSCLC with the same pathological stage. The RCS curve showed an inverted L-shaped dose-response relationship between the IBI and survival of patients with NSCLC. Multivariable Cox proportional hazards regression analysis showed that a high IBI was an independent risk factor for death of patients with NSCLC (hazard ratio = 1.229, 95% confidence interval [CI]: 1.131-1.335, P < 0.001). A high IBI was an independent predictor of 90-day outcomes (odds ratio [OR] = 1.789, 95% CI: 1.489-2.151, P < 0.001), prolonged hospital stays (OR = 1.560, 95% CI: 1.256-1.938, P < 0.001), high hospitalization expenses (OR = 1.476, 95% CI: 1.195-1.822, P < 0.001) and cachexia (OR = 1.741, 95%CI = 1.374-2.207, P < 0.001) in patients with NSCLC.
conclusionsThe IBI was independently associated with overall survival, 90-day outcomes, length of hospitalization, hospitalization expenses and cachexia in NSCLC patients. As an optimal systemic inflammation biomarker, the IBI has broad clinical application prospects in predicting the prognosis of patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.